Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Dynavax Technologies Corp Market Cap
From what 5 stock analysts predict, the share price for Dynavax Technologies Corp (DVAX) might increase by 91.29% in the next year. This is based on a 12-month average estimation for DVAX. Price targets go from $15 to $29. The majority of stock analysts believe DVAX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
DVAX is a stock in Healthcare which has been forecasted to be worth $24.6 as an average. On the higher end, the forecast price is $29 USD by Edward White from HC Wainwright & Co. and on the lower end DVAX is forecasted to be $15 by Edward White from HC Wainwright & Co..
These are the latest 20 analyst ratings of DVAX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Edward White HC Wainwright & Co. | Buy | $29 | Reiterates | Nov 8, 2024 |
| Edward White HC Wainwright & Co. | Buy | $29 | Reiterates | Oct 15, 2024 |
| Paul Choi Goldman Sachs | Neutral | $15 | Maintains | Aug 8, 2024 |
| Edward White HC Wainwright & Co. | Buy | $29 | Reiterates | Aug 7, 2024 |
| Edward White HC Wainwright & Co. | Buy | $29 | Reiterates | Jun 28, 2024 |
| Edward White HC Wainwright & Co. | Buy | $29 | Reiterates | May 14, 2024 |
| Edward White HC Wainwright & Co. | Buy | $29 | Reiterates | May 9, 2024 |
| Paul Choi Goldman Sachs | Neutral | $20 | Initiates | Feb 1, 2024 |
| Edward White HC Wainwright & Co. | Buy | $28 | Maintains | Nov 3, 2023 |
| Roy Buchanan JMP Securities | Market Outperform | $27 | Maintains | Nov 3, 2023 |
| Edward White HC Wainwright & Co. | Buy | $27 | Reiterates | Aug 4, 2023 |
| Roy Buchanan JMP Securities | Outperform | $25 | Maintains | Aug 4, 2023 |
| Roy Buchanan JMP Securities | Outperform | $24 | Maintains | May 3, 2023 |
| Edward White HC Wainwright & Co. | Buy | $27 | Reiterates | May 3, 2023 |
| Edward White HC Wainwright & Co. | Buy | $27 | Maintains | Feb 24, 2023 |
| Roy Buchanan JMP Securities | Market Outperform | $25 | Maintains | Feb 24, 2023 |
| Madhu Kumar Goldman Sachs | Buy | $21 | Maintains | Nov 4, 2022 |
| Roy Buchanan JMP Securities | Market Outperform | $22 | Initiates | Sep 27, 2022 |
| Edward White HC Wainwright & Co. | Buy | $28 | Maintains | Dec 29, 2021 |
| Edward White HC Wainwright & Co. | Buy | $23 | Maintains | Aug 31, 2021 |
When did it IPO
2004
Staff Count
408
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Ryan Spencer
Market Cap
$1.70B
In 2023, DVAX generated $232.3M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that DVAX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Dynavax Technologies (Nasdaq: DVAX) will present at the Evercore HealthCONx Conference on December 3 at 2:35 p.m., focusing on its innovative vaccine developments.
Why It Matters - Dynavax's presentation at a key health conference could signal potential advancements in vaccine development, influencing investor sentiment and stock performance.
Wed, 27 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Wall Street analysts project a 93.5% upside for Dynavax Technologies (DVAX), supported by positive earnings estimate revisions.
Why It Matters - A 93.5% upside in price targets suggests strong growth potential for Dynavax Technologies, while positive earnings revisions may further boost investor confidence and stock performance.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Dynavax Technologies has initiated a $100 million Accelerated Share Repurchase agreement with Goldman Sachs to buy back its common stock.
Why It Matters - Dynavax's $100 million share repurchase signals confidence in its financial health and could boost earnings per share, potentially increasing stock value and attracting investor interest.
Mon, 11 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Dynavax Technologies (DVAX) has a consensus price target suggesting an 88.3% upside. Earnings estimate revisions are trending upward, indicating potential near-term gains.
Why It Matters - An 88.3% upside potential suggests significant growth for Dynavax Technologies (DVAX), and rising earnings estimates indicate positive momentum, which could attract investor interest.
Mon, 11 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Dynavax Technologies (DVAX) has been upgraded to Zacks Rank #2 (Buy), indicating improved earnings prospects, which may positively impact the stock price in the near term.
Why It Matters - The Zacks Rank #2 upgrade signals positive earnings outlook for Dynavax Technologies, potentially boosting investor confidence and driving the stock price higher.
Wed, 13 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Dynavax Technologies announced a significant buyback authorization, and its product Heplisav-B is gaining market share. Analysts have set price targets above current levels, indicating potential growth.
Why It Matters - Dynavax's buyback boosts shareholder value, while Heplisav-B's market growth indicates strong revenue potential. Analyst price targets suggest further upside, enhancing investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
